Clinical Trial Update: Long-Term Open-Label, Safety Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension Patients [Phase 3]

View source ↗

Summary

Phase 3 long-term open-label safety study of sitaxentan sodium in Japanese patients with pulmonary arterial hypertension was terminated; results were posted in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• sitaxentan sodium (sitaxentan)

Snippet

Sponsor: Pfizer | Conditions: Hypertension, Pulmonary | Phase 3 | Status: TERMINATED | Results posted: 2011-12-14